Merck

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at canceriq.com.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.

Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.

Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.

Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).

Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication. Oncolmmune was founded in 2000 and is based in Rockville, Maryland.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Volansi, Inc. is a logistics and transportation company specializing in the manufacture of heavy-payload drones for commercial, defense, and humanitarian purposes. Founded in 2015 and headquartered in Concord, California, Volansi develops autonomous aerial delivery solutions that enable time-critical shipments over long distances. The company’s unmanned aerial vehicles are designed for various industries, including construction, oil and gas, mining, and healthcare, facilitating the rapid delivery of essential items such as spare parts and medical supplies. By offering fixed-route deliveries, Volansi addresses specific customer challenges related to time and cost, allowing businesses to enhance their operational efficiency.

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

AeroSafe Global specializes in the development and production of aerogels and related materials designed for temperature-sensitive shipping needs. Operating primarily in the United States, the company addresses thermal insulation requirements for transporting biomedical, pharmaceutical, and other temperature-sensitive products. AeroSafe Global offers cold-chain services tailored for the biopharma industry, ensuring zero temperature excursions for clients and their products. Through proprietary packaging, logistics, and operational services, the company creates customized solutions that guarantee the safe delivery of sensitive biopharmaceuticals. Founded in 1995 and headquartered in Rochester, New York, AeroSafe Global also maintains additional offices in Kentucky, Nevada, Germany, and Canada.

Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials. Zapata Computing is a spun out of Harvard University launched by a group of Harvard scientists, including Alán Aspuru-Guzik. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Tasso, Inc. is a healthcare company based in Seattle, Washington, that specializes in the development of clinical-grade blood sample collection devices. Founded in 2012, Tasso has created innovative self-sampling devices that allow patients to collect their own blood at home with ease and convenience. These disposable devices are designed for user-friendliness, enabling individuals to obtain blood samples painlessly and securely. After collection, patients can mail the samples directly to qualified laboratories for analysis. Tasso's approach prioritizes patient comfort and privacy, fundamentally transforming the traditional blood collection process.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company focused on creating immunotherapies for various human diseases. Established in 2014 and headquartered in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, the company utilizes advanced antibody science to develop large-scale production platforms for immunoglobulins. Its product pipeline includes SAB-142, which targets Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 aimed at Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SAB Biotherapeutics is committed to addressing public health challenges, rare conditions, long-term diseases, and potential global pandemic threats through innovative therapeutic solutions.

Preventice Solutions, Inc. is a provider of healthcare solutions specializing in mobile health technologies and services. Founded in 2007 and based in Eagan, Minnesota, the company offers a range of platforms, including the PatientCare Portal for real-time patient data management, the PatientView Portal for healthcare organizations, and the PatientFlow Portal for monitoring centers. Preventice is known for its advanced wearable monitoring devices, such as the BodyGuardian Heart, which enhances patient mobility and compliance, and the BodyGuardian Verité, a dual-modality cardiac sensor. These technologies aim to facilitate the monitoring and management of patients with cardiac issues, improving health outcomes while potentially reducing the cost of care. The company was formed through the merger of Preventice Services and Preventice Technologies in 2014, and it operates additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing games and applications aimed at managing chronic health conditions and enhancing patient adherence. Founded in 2008, Ayogo utilizes behavioral psychology and social gaming principles to improve health outcomes. Its flagship product, GoodLife, offers a customizable platform featuring gamification elements, incentives, and social interactions to engage users effectively. Additionally, Ayogo's Alternate Reality Games provide a suite of learning applications that blend online and real-world experiences. The company collaborates closely with patients, end-users, and clients, which include insurers, healthcare providers, and pharmaceutical companies. By focusing on psychosocial factors, Ayogo's platform enhances patient activation, adherence, and persistence in treatment, ultimately aiming to foster healthier patients and better financial outcomes for healthcare organizations.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for cancer and rare diseases. Based in Burlington, Massachusetts, the company utilizes its ArQule Kinase Inhibitor Platform to create innovative small molecule drugs. ArQule's pipeline includes several promising candidates, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase currently in Phase I trials for B-cell malignancies, and miransertib (ARQ 092), which targets the AKT pathway in advanced endometrial cancer patients. Additionally, ARQ 75 is under Phase I development for solid tumors with specific genetic mutations, while Derazantinib (ARQ 087) is in a registrational trial for intrahepatic cholangiocarcinoma. The company has established licensing agreements with Basilea Pharmaceutica and Roivant Sciences for its products. Founded in 1993, ArQule has positioned itself as a key player in the oncology space, aiming to improve patient outcomes through its specialized therapeutics. As of early 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

She's Well is a fertility management service that utilizes a subscription model to assist individuals and couples in starting families at their own pace. The company partners with leading fertility centers to provide financial plans for various services, including fertility testing, IVF, egg freezing, and sperm freezing. By adopting an on-demand concierge care approach, She's Well aims to simplify the often complex and isolating fertility journey. With one in six couples facing challenges in conception and a growing trend of delayed childbirth, She’s Well addresses a significant gap in infertility services, which currently reach only a small percentage of those in need. Typical costs for treatments like IVF can be prohibitively high, often ranging from $12,000 to $20,000, with additional expenses for genetic testing. She's Well seeks to make fertility care more affordable and accessible, promoting a future where family planning is not constrained by biological timelines and where comprehensive care options are available to all who wish to conceive.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

CIOX Health, LLC is a healthcare services company based in Alpharetta, Georgia, specializing in the management and exchange of health information. The firm operates a cloud-based platform that digitizes and organizes both structured and unstructured medical records, facilitating access to clinical data for various stakeholders, including healthcare providers, health plans, and government agencies. CIOX offers a range of services including information release, medical record retrieval, coding and education, and risk adjustment solutions. Their expertise is designed to improve patient outcomes while ensuring compliance with regulations regarding the release of medical information. CIOX Health serves a diverse clientele, including hospitals, physician practices, law firms, and life insurance companies, making it a key player in the healthcare information management sector. The company was established in 1976 and operates additional locations in Phoenix, Arizona, and Green Bay, Wisconsin.

Tilos Therapeutics, Inc. is a biotechnology company focused on developing antibody therapeutics aimed at treating cancer. Established in 2016 and based in Lexington, Massachusetts, the firm specializes in anti-LAP antibodies that target key immunological pathways, particularly regulatory T cells and the regulation of effector cells. Its primary research involves antibodies specific for the Latency Associated Peptide of TGF beta, which plays a critical role in immune regulation. As of mid-2019, Tilos Therapeutics operates as a subsidiary of Merck & Co., Inc.

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, specializing in 3D bioprinting and tissue engineering. Founded in 2013, the company develops advanced living tissues through its proprietary microfluidic 3D bioprinting platform. This technology allows for precise control over biomaterial composition and structure during tissue fabrication, facilitating research in areas such as respiratory diseases. Aspect also provides contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical companies and academic institutions. In addition to its core offerings, Aspect is advancing internal programs focused on regenerative medicine, particularly for metabolic diseases and musculoskeletal disorders, while collaborating with industry partners to commercialize bioprinted therapeutics.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, focused on developing innovative medicines for cancer and other serious conditions. The company's lead candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma. Additionally, Peloton is exploring PT2977 in various other indications, including von Hippel-Lindau disease-associated renal cell carcinoma and glioblastoma multiforme, as well as in combination therapies for metastatic renal cell carcinoma. Furthermore, Peloton is developing PT2567, another oral HIF-2a inhibitor in preclinical stages aimed at non-oncology applications, notably pulmonary arterial hypertension. Founded in 2010 and initially known as Damascus Pharmaceutics, Peloton Therapeutics has formed strong partnerships with academic institutions and secured funding from organizations like the Cancer Prevention Research Institute of Texas, positioning itself as a key player in the biotech sector.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Clinithink Ltd is a healthcare software company based in Bridgend, United Kingdom, that specializes in cloud-based data analytics solutions. Founded in 2009, the company has developed a platform known as CLiX, which employs Natural Language Processing (NLP) to convert unstructured clinical narratives into structured data. This technology allows healthcare providers, pharmaceutical companies, and content vendors to collect and analyze clinical trial data effectively. Clinithink's products include CLiX ENRICH, which facilitates the indexing and recording of clinical trial data in a preferred narrative format, and CLiX RARE, aimed at diagnosing genetic disorders in newborns. Through its innovative approach, Clinithink supports healthcare applications in data analytics, coding, and decision-making.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Kytopen Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on advancing cell therapy through its innovative Flowfect technology. Established in 2017, Kytopen specializes in non-viral delivery systems for molecules into challenging immune cells that are typically hard to transfect. The company utilizes a combination of microfluidics and automation to streamline the delivery process, making it faster, more efficient, and cost-effective. By employing a unique platform that integrates continuous fluid flow with electric fields, Kytopen enables researchers to produce high-quality engineered cells in a matter of minutes while preserving their health and functionality. This approach supports the discovery of novel biological insights and the development of affordable cell and gene therapies.

Antelliq specializes in animal intelligence solutions that enhance the management of livestock, pets, and fish through innovative identification, traceability, and monitoring technologies. The company offers a range of products that provide critical data to veterinarians, farmers, and pet owners, thereby improving the health and well-being of animals. Operating under well-known brands such as Allflex, Sure Petcare, and Biomark, Antelliq has a global presence, serving customers in over 100 countries and employing more than 1,900 people. With a history of over 60 years in the industry, Antelliq emphasizes real-time data to enable better herd management for farmers and offers smart devices to help pet owners monitor their pets' health. The company also engages in conservation efforts, supporting the protection of natural environments and wildlife. Antelliq’s innovation is driven by its four specialized Innovation Centers located in Israel, France, the UK, and the US, which focus on different aspects of animal intelligence technology, leveraging extensive research and development expertise to continuously improve animal health solutions.

ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.

Quit Genius is a digital behavior change platform for addictions with industry-leading quit rates. Founded in 2017 by medical doctors, the program for tobacco, e-cigarettes, alcohol and substance use disorder uses a disruptive model to deliver best practice care via digital cognitive behavioral therapy (CBT), expert coaching, a connected breath sensor and easy access to proven medication.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia. Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Prognos Health is a prominent health tech company specializing in healthcare analytics aimed at improving disease management and treatment decision-making. Its platform, prognosFACTOR, allows users to quickly query billions of lab and health records from over 325 million de-identified patients, significantly reducing the time needed to answer critical healthcare questions. The Prognos Registry serves as the largest source of clinical diagnostics information across more than 30 disease areas, encompassing over 5 billion medical records for 100 million patients. By employing a suite of 500 proprietary clinical algorithms, Prognos facilitates earlier patient identification, enhancing treatment decisions and risk management. The company collaborates with key stakeholders in the healthcare ecosystem, including pharmaceutical manufacturers and payers, providing HIPAA-compliant patient-centric data through the Prognos Marketplace for various applications such as cohort design and health outcomes analysis.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.

Serimmune Inc. is a biotechnology company focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014 and based in Goleta, California, the company utilizes its serum epitope repertoire analysis (SERA) technology platform, which integrates bacterial display peptide libraries, sequencing, machine learning, and bioinformatics. This platform enables the mapping of distinct antibodies within an immune repertoire to specific antigens linked to infections, allergens, microbiome organisms, autoimmune diseases, and cancers. By providing insights into the immune response, Serimmune aims to facilitate the creation of new diagnostics, vaccines, and therapeutics, thereby enhancing the ability of medical practitioners to address various health challenges.

ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

Arcadia Solutions, LLC specializes in electronic health record (EHR) data aggregation and analytics for the healthcare industry. Founded in 2002 and based in Burlington, Massachusetts, the company delivers a range of services and proprietary software to large healthcare providers, payors, accountable care organizations, and health information exchanges. Arcadia focuses on integrating data from over 30 EHR platforms and enhances it with claims and operational data to improve patient care quality, practice efficiency, and financial performance. The company offers IT services tailored for accountable care organizations, consulting services, EHR implementation and optimization, health systems performance management, and information security. Additionally, Arcadia provides a customizable suite of solutions for managing health IT infrastructures and technology systems, including a service desk, performance monitoring, and hardware lifecycle management. Its clients include hospitals, large health systems, independent practice associations, and community health centers across the nation.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.

StayWell Company is a health engagement firm that specializes in patient education and population health management services. It serves a diverse range of clients, including businesses, government entities, and healthcare associations. By leveraging extensive experience in the healthcare sector, StayWell designs customizable solutions that facilitate health engagement and foster behavior change. The company offers a comprehensive portfolio of services that includes health information dissemination, educational programs, and marketing engagement strategies. StayWell's approach is data-driven, ensuring that each phase of program development—from design to implementation and performance evaluation—reflects measurable outcomes. As a result, clients benefit from reduced health costs, increased participation rates, enhanced patient acquisition, improved health outcomes, and high levels of program satisfaction.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

IOmet Pharma Ltd. discovers and develops medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. It develops IDO, TDO, and dual-acting IDO/TDO inhibitors, as well as GLUT1 inhibitors. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in London, United Kingdom. As of January 11, 2016, IOmet Pharma Ltd. operates as a subsidiary of Merck & Co., Inc.

WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.

Exostar is a provider of secure cloud-based solutions that enhance collaboration, information sharing, and supply chain management for over 100,000 organizations globally, particularly in aerospace and defense, life sciences, pharmaceuticals, and financial services. The company offers a single-sign-on identity and access management platform along with multi-enterprise collaboration tools, allowing users to efficiently connect and access critical applications and information across various partners and vendors. Exostar's platform is designed to help organizations mitigate risk, protect intellectual property, streamline partner lifecycles, and expedite supply chain processes, all while ensuring compliance with contractual and regulatory requirements. By improving security and reducing costs, Exostar enables its clients to enhance agility and strengthen their relationships with partners.

CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.

Hangzhou Just Biotherapeutics, Ltd., also known as Just China, is a biotechnology company founded in 2016 and located in Hangzhou, China. The company specializes in developing antibody and recombinant protein biotherapeutics, focusing on accelerating the development of biomedicines while significantly reducing manufacturing costs. It excels in molecular design, process design, drug product design, and the design of manufacturing facilities. Initially a subsidiary of Just Biotherapeutics, Inc., it became a subsidiary of MabSpace Biosciences Co., Ltd. in January 2019.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.

ClearDATA Networks, Inc. specializes in healthcare cloud computing and information security solutions, catering to healthcare providers, life sciences organizations, and payers. Founded in 2009 and headquartered in Austin, Texas, with additional offices in San Francisco and Scottsdale, the company offers a multi-cloud platform that automates, protects, and manages healthcare applications and data. Key offerings include ClearDATA Comply, which helps organizations ensure cloud compliance with privacy regulations; ClearDATA Assess, designed for conducting mandatory HIPAA Security Risk Assessments; and ClearDATA Locate Mask, which enables healthcare organizations to utilize sensitive data safely by masking personal information. ClearDATA's HITRUST-certified cloud is recognized for its robust security and compliance solutions, providing a comprehensive Business Associate Agreement (BAA) and enabling clients to improve data management while minimizing privacy risks. The company's services extend to process design, solution architecture, custom development, and security risk assessments, empowering the healthcare sector to enhance service delivery through advanced analytics and scalable IT infrastructure.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Ayogo Health Inc. is a Vancouver-based company that specializes in developing games and applications aimed at managing chronic health conditions and enhancing patient adherence. Founded in 2008, Ayogo utilizes behavioral psychology and social gaming principles to improve health outcomes. Its flagship product, GoodLife, offers a customizable platform featuring gamification elements, incentives, and social interactions to engage users effectively. Additionally, Ayogo's Alternate Reality Games provide a suite of learning applications that blend online and real-world experiences. The company collaborates closely with patients, end-users, and clients, which include insurers, healthcare providers, and pharmaceutical companies. By focusing on psychosocial factors, Ayogo's platform enhances patient activation, adherence, and persistence in treatment, ultimately aiming to foster healthier patients and better financial outcomes for healthcare organizations.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

Liaison Technologies provides data management and integration solutions to integrate, transform, harmonize, manage, and secure critical business data on-premise or in the cloud. It offers business-to-business and application-to-application integration, and data transformation services; on-premise and cloud-based data security solutions; cloud integration brokerages, and data aware cloud services; data harmonization solutions; cloud-based master data management; architecture-based B2B integration network; and compliance solutions. Liaison Technologies offers its solutions for the secure exchange of patient data between providers, payers, patients, and other healthcare organizations; for life science research endeavors; and to integrate and manage mission-critical data to improve efficiencies in forecasting, inventory management, material procurement, stock replenishment, order fulfillment, and other manufacturing processes. In addition, it provides data cleansing, semantic parsing, and up-to-the-minute product data; and electronic documents for handling and providing communications between manufacturers, distribution centers, shippers, transportation carriers, and other companies. Further, Liaison Technologies offers managed, cloud, professional, and cost optimization services, as well as planning, implementation, and other services. It serves healthcare, life sciences, manufacturing, retailers, consumer product goods providers and suppliers, logistics and distribution, and financial services companies in the United States and internationally. ForestExpress began operation in 2000 that became Liaison Technologies in April 2004. Its headquarters is in Alpharetta in Georgia with additional offices in Carbondale in Illinois, Santa Barbara and Silicon Valley in California; Seattle in Washington, Helsinki and Tampere in Finland, Nottingham in the United Kingdom, Amsterdam, the Netherlands; Stockholm, Sweden; and Singapore.

Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Aventura intelligently orchestrates assets, people, and systems to deliver the right information at the right time based on location and credentials. It locates and re-assigns the closest online printer and uniquely manages print routing to make it easier to detect and fix printing failures. Aventura was formed in 2007 and headquartered in Denver, Colorado.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Cubist Pharmaceuticals is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in acute care settings. The company is known for marketing CUBICIN (daptomycin for injection), a groundbreaking antibiotic in the lipopeptide class, as well as ENTEREG (alvimopan), which facilitates gastrointestinal recovery after certain surgeries. Cubist also promotes MERREM I.V. (meropenem for injection), an established antibiotic developed by AstraZeneca. Its product pipeline includes ecallantide, currently in Phase 2 clinical trials, and ongoing research focused on reducing blood loss during cardiac surgery. Additionally, the company is exploring treatments for Clostridium difficile-associated diarrhea and multi-drug resistant Gram-negative infections. In collaboration with Alnylam Pharmaceuticals, Cubist is also developing novel therapies for respiratory syncytial virus infections using RNA-interference technology. Founded in 1992 and headquartered in Lexington, Massachusetts, Cubist Pharmaceuticals continues to advance its mission of improving patient outcomes in acute care environments.